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Abstract
 
Recombination activating gene (
 
RAG
 
) expression in peripheral B cells increases after immuni-
zation with (4-hydroxy-3-nitrophenyl) acetyl coupled to chicken gamma globulin (NP-CGG)
in alum. This increase could result from reinduction of 
 
RAG
 
 expression or, alternatively, from
accumulation of 
 
RAG
 
-expressing immature B cells in the periphery. We have used mice that
carry a green fluorescent protein (GFP) RAG indicator transgene (
 
RAG2-GFP
 
) to characterize
the 
 
RAG
 
-expressing B cells in immunized spleens. Most of the 
 
RAG2-GFP
 
–expressing B cells
in unimmunized spleen are immature B cells. Injection with NP-CGG in alum initially sup-
presses lymphopoiesis in the bone marrow and decreases the number of immature 
 
RAG2-
GFP–
 
expressing B cells in the spleen. Recovery of lymphopoiesis in the bone marrow coin-
cides with accumulation of RAG-expressing immature B cells in the spleen. Most of the
RAG-expressing cells that accumulate in the spleen after immunization do not proliferate and
they are not germinal center cells. Neither the initial suppression of lymphopoiesis nor the sub-
sequent accumulation of RAG-expressing cells in the spleen is antigen dependent, since similar
changes are seen with alum alone. Furthermore, such changes in the numbers of developing
and circulating immature lymphoid cells are seen after injection with complete Freund’s adju-
vant or malaria infection. Our experiments suggest that adjuvants and infectious agents cause
previously unappreciated alterations in lymphopoiesis resulting in the accumulation of RAG-
expressing immature B cells in the spleen.
Key words: recombination activating gene • adjuvant • malaria • lymphocyte development • 
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Introduction
 
Recombination activating genes 1 and 2 (
 
RAG1
 
 and
 
RAG2
 
)
 
1
 
 encode a lymphocyte-specific enzyme that cata-
lyzes 
 
V(D)J
 
 recombination (1–3). In the B lymphoid lin-
eage, 
 
RAG
 
 expression is primarily restricted to developing
B cells in the bone marrow (4, 5). However, low level
 
RAG
 
 expression is also found in B cells in peripheral lym-
phoid organs, and several laboratories have reported in-
creases in 
 
RAG
 
 expression in peripheral B cells after im-
munization (6–9). Two hypotheses have been put forward
to account for this increase: RAG expression could be re-
induced in B cells undergoing antigen-activated immune
responses (6, 7); alternatively, RAG expression in the pe-
riphery might reflect accumulation of immature B cells
containing residual RAG mRNA (6, 7, 10).
To examine regulation of 
 
RAG2
 
 expression in vivo, we
and others produced mice that carry 
 
RAG2
 
 green fluores-
cent protein (
 
RAG2-GFP
 
) indicator genes (9–11). Al-
though there were several differences in the techniques
used to produce the indicator strains, the results of the ex-
periments were similar: 
 
RAG2-GFP
 
 expression was found
in spleen B cells, and in both cases it was the immature B
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Abbreviations used in this paper:
 
 APC, allophycocyanin; B6, C57BL/6;
CGG, chicken gamma globulin; GC, germinal center; GFP, green fluo-
rescent protein; HSA, heat-stable antigen; LCMV, lymphocytic chorio-
meningitis virus; NP, (4-hydroxy-3-nitrophenyl) acetyl; PRBC, parasite-
infected BALB/c red blood cell; 
 
RAG
 
,
 
 
 
recombination activating gene;
RT, reverse transcription; STAT, signal transducer and activator of tran-
scription. 
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cells that expressed the indicator (9, 10). However, the
source of the increased 
 
RAG
 
 expression observed after im-
munization was not determined (9, 10).
Here we report experiments showing that transient in-
creases in RAG expression in the spleens of immunized
mice result from changes in the production of immature B
cells and their export from the bone marrow.
 
Materials and Methods
 
Mice.
 
RAG2-GFP (FVB/N or [FVB/N 
 
3
 
 C57BL/6 (B6)]
F1) mice (10), TNF knockout (TNF
 
2
 
/
 
2
 
) (12), type I IFN recep-
tor knockout (IFNR
 
2
 
/
 
2
 
) (13), and signal transducer and activator
of transcription (STAT)1 knockout (STAT1
 
2
 
/
 
2
 
) (14) mice and
matched controls were bred and maintained under specific patho-
gen-free conditions. B6, RAG1 knockout (RAG1
 
2
 
/
 
2
 
), and 129S6/
SvEv mice were purchased from The Jackson Laboratory or
Taconic Farms. Mice were 2–5 mo old and were always age and
sex matched.
 
Immunization.
 
400 
 
m
 
l 10% aluminum potassium sulfate with
or without 100 
 
m
 
g of (4-hydroxy-3-nitrophenyl) acetyl (NP)
coupled to chicken gamma globulin (NP-CGG; Biosearch Tech-
nologies, Inc.) was precipitated by adjusting pH to 6.2 with 1 N
potassium hydroxide; the alum precipitates were washed in PBS
three times and injected intraperitoneally. CFA (Sigma-Aldrich)
was mixed with an equal volume of PBS, and 200 
 
m
 
l was injected
intraperitoneally.
 
Malaria Infection. Plasmodium yoelii 
 
(17X NL strain) was main-
tained by alternating cyclic passage of the parasites in 
 
Anopheles
stephensi 
 
mosquitoes and BALB/c mice. Before infecting B6
mice, parasites were passed in this strain by injecting the mice
with parasite-infected BALB/c red blood cells (PRBCs). For ex-
perimental infections in B6 mice, 1 
 
3
 
 10
 
3
 
 PRBCs obtained from
B6 mice were injected intraperitoneally, and parasitemia was de-
termined by microscopic examination of Giemsa-stained thin
blood smears (15).
 
Adoptive Transfer.
 
Adoptive transfer was performed as de-
scribed (10). 2–4 
 
3
 
 10
 
7
 
 splenocytes from wild-type B6 or
RAG2-GFP ([FVB/N 
 
3
 
 B6]F1) mice were transferred by intra-
venous injection into B6 RAG1
 
2
 
/
 
2
 
 recipients.
 
Flow Cytometry and Cell Sorting.
 
The following anti–mouse
antibodies were used: biotin, PE, or allophycocyanin (APC) anti-
B220 (RA3-6B2); biotin or FITC anti-CD43 (S7); biotin or PE
anti–heat-stable antigen (HSA) (M1/69); biotin anti-IgM (R6-
60.2); biotin anti-Ig
 
l
 
1
 
l
 
2 (R26-46); biotin anti-Ig
 
k
 
 (R5-250);
GL7; biotin anti-CD4 (H129.19); APC anti-CD8 (Ly-2); PE
anti-Fas (Jo2); biotin anti–Ly-6G (RB6-8C5); PE DX5; FITC
annexin V; and FcBlock (2.4G2) (all from BD PharMingen). Bi-
otinylated antibodies were visualized with streptavidin–Red 613
(GIBCO BRL) or streptavidin-PerCP (Becton Dickinson). GL7
was visualized using PE- or biotin-labeled mouse anti–rat IgM.
For DNA staining, cells were suspended in 20 
 
m
 
M Hoechst
33342 (Molecular Probes)/2% fetal bovine serum/PBS and incu-
bated at 37
 
8
 
C for 40 min. Data were acquired with a FACSCali-
bur™ or FACS Vantage™ (Becton Dickinson) and analyzed
with CELLQuest™ software (Becton Dickinson). Nucleated
lymphocytes were electronically gated on forward and side scat-
ter; for DNA analysis, doublets were excluded by area and width
of FL-5 signal pulses. For RNA analysis, spleen cells stained with
anti-B220, anti-HSA, and anti-IgM antibodies and fractions of
cells (1–2 
 
3
 
 10
 
5
 
) were sorted directly into TRIzol LS (GIBCO
BRL).
 
Reverse Transcription PCR.
 
RNA was extracted using TRI-
zol (GIBCO BRL), and cDNA was synthesized using Superscript
II reverse transcriptase (GIBCO BRL). Reverse transcription
(RT)-PCR reactions were performed on serial dilutions of
cDNA template using HotStarTaq polymerase (Qiagen). PCR
conditions and primers were as described (10). Specificity of PCR
products was confirmed by Southern blotting as described (16).
The oligonucleotide probe used for Ig
 
b
 
 
 
was 5
 
9
 
-GTGACCTGC-
CACTGAATTTCCAAG-3
 
9
 
.
 
Results
 
Half-Life of GFP
 
 
 
Expression in Immature B Cells In Vivo.
 
GFP
 
1
 
 B cells in the spleens of RAG2-GFP mice display
the surface features of immature B cells (B220
 
low
 
HSA
 
high
 
493
 
1
 
) (10), whereas GFP
 
2
 
 B cells are mature B cells (B220
 
high
 
HSA
 
low
 
493
 
2
 
) (10, 17, 18). Upon transfer to RAG
 
2
 
/
 
2
 
 re-
cipients, GFP
 
1
 
 B cells become GFP
 
2
 
 and home to lymph
nodes and spleen, suggesting that they mature and enter the
long-lived B cell compartment (10). To determine the ki-
netics of loss of GFP expression, we transferred spleen cells
from RAG2-GFP indicator mice into RAG1
 
2
 
/
 
2
 
 recipients
(Fig. 1 A). After adoptive transfer the number of GFP
 
high 
 
B
cells decreased with a half-life of 52 h (Fig. 1 A), and after
4 d these cells were no longer found in RAG
 
2
 
/
 
2
 
 recipients.
Similar kinetics of loss of GFP expression were found when
GFP
 
1
 
 spleen B cells were cultured in vitro (10; and not
shown). Therefore, it is unlikely that GFP
 
1
 
 cells preferen-
tially migrate out from spleen. We conclude that 
 
RAG2-
GFP
 
 is only expressed for a short time after B cells leave
the bone marrow, and that GFP
 
1
 
 B cells are not generated
from spleen B cell precursors.
To confirm that loss of 
 
RAG2-GFP
 
 expression corre-
lates with loss of endogenous RAG mRNA, we measured
RAG1 mRNA by RT-PCR. Spleen cells were transferred
into RAG1
 
2
 
/
 
2
 
 mice, and B220
 
1
 
HSA
 
high
 
 cells were puri-
fied after 7 d. RAG1 mRNA could not be detected in the
transferred B cells, whereas immature spleen B cells from a
wild-type control were positive for RAG1 mRNA expres-
Figure 1. Adoptive transfer of
RAG2-GFP mouse splenocytes
into RAG12/2 mice. (A) Per-
centage of GFPhigh cells in IgM1
population recovered from
RAG2/2 mouse spleen, moni-
tored at 24-h intervals after adop-
tive transfer (four mice per time
point). The curve was fitted
using Deltagraph™ software
(DeltaPoint, Inc.). (B) RAG1
mRNA expression in B cells
purified from the spleens of
RAG12/2 mice that had received
2–4 3 107 wild-type spleen cells
7 d earlier. Serial fivefold dilu-
tions of the cDNA are shown.
PCR for Igb is a cDNA loading
control. R1, RAG1; TRSF, B cells isolated from RAG12/2 adoptive
transfer recipient; WT, unmanipulated wild-type mouse B cells. 
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sion (Fig. 1 B). We conclude that 
 
RAG2-GFP
 
 expression
after transfer correlates with endogenous RAG mRNA ex-
pression and that 
 
RAG
 
-expressing immature B cells are not
of splenic origin.
 
The Number of Immature B Cells Is Regulated during Im-
mune Responses.
 
Experiments in several laboratories have
shown that B cell 
 
RAG
 
 expression increases in peripheral
lymphoid organs after immunization (6–9). To determine
whether immunization also increases 
 
RAG2-GFP
 
 expres-
sion, we injected indicator mice with NP-CGG in alum
and performed time course experiments (Fig. 2 A). Al-
though the number of immature GFP
 
1
 
 B cells in the spleen
initially decreased (34 
 
6 
 
15% of control [
 
n
 
 5 
 
5]; Fig 2 A),
by day 16 their number had increased above the starting
value (199 
 
6 
 
38% of control [
 
n
 
 5 6]; Fig 2 A). Both the
timing and magnitude of this transient increase in RAG ex-
pression are consistent with previous observations (6, 7, 9).
The GFP1 B cells in the spleen on day 16 after immuni-
zation were heterogeneous and showed an increased pro-
portion of less mature IgMlow B cells (Fig. 2 A). In contrast,
there was no shift in the surface IgM expression in GFP2
B cells with immunization. To confirm that changes in
RAG2-GFP expression after immunization reflect changes
in endogenous RAG mRNA expression, we compared
RAG1 mRNA levels in GFP1 and GFP2 B cells purified
from spleens of immunized and control mice. Endogenous
RAG1 mRNA was found in GFP1 but not in GFP2 cells,
and the level of RAG1 expression per cell increased after
immunization (Fig. 2 B). The relative increase in RAG1
expression in GFP1 B cells may reflect a relative increase in
less mature IgMlow cells, since these are known to express
higher levels of RAGs than IgMhigh immature B cells (Fig.
2 A, middle panels [9, 10]). We conclude that the number
of RAG-expressing immature B cells in the spleen increases
after immunization with NP-CGG in alum. Finally, the in-
crease in RAG2-GFP expression in spleen at day 16 was
transient and the number of GFP1 B cells returned to nor-
mal by day 28 after immunization (Fig. 2 A). Interestingly,
the number of immature B lineage cell in the bone marrow
also varied during the response, but GFP intensity was not
significantly altered by immunization (Fig. 2 A, and data
not shown).
As noted above, the majority of the GFP1 B cells in un-
immunized spleens are not derived from splenic precursors.
To determine whether immunization induces spleen B
cells to express RAG2-GFP, we performed adoptive trans-
fer experiments. Spleen cells from RAG2-GFP indicator
mice were transferred into RAG12/2 hosts that were im-
munized on day 1 after transfer. Although the immunized
recipients showed an increase in spleen GL71 B cells con-
sistent with an ongoing immune response, we found no in-
crease in GFP1 B cells at day 16 after adoptive transfer of
spleen cells (Fig. 2 C). We conclude that the GFP1 B cells
found in the spleen at day 16 after immunization are not
generated from splenic precursors.
To determine whether GFP1 B cells in the spleen at day
16 after immunization were dividing, we measured their
DNA content with Hoechst dye. In seven independent ex-
periments, only 1.18 6 0.52% of the GFP1 B cells had S or
G2/M phase DNA content. Most of these cycling cells
were found in a GL7lowB220low but Fas2 subpopulation of
GFP1 cells (Fig. 3, A and B; see gate G2). Therefore, most
of the GFP1 B cells in the spleens of immunized RAG2-
GFP indicator mice are not germinal center (GC) cells,
which are predominantly GL7high and Fas1 (Fig. 3, A and
B; see gate G1) (6, 19, 20).
Figure 2. RAG2 expression in peripheral B cells
in immune responses. (A) RAG2-GFP expression
in mice injected with NP-CGG in alum. The first
row shows GFP intensity on B2201 spleen cells.
The second and third rows show IgM intensity
(bold lines) on GFP1B2201 and GFP2B2201
spleen cells; dotted lines indicate B2202 cell con-
trols. The fourth row shows B220/IgM density
plots of bone marrow (BM) cells. Numbers are the
percentages of gated cells or absolute cell numbers
3106 (shown in parentheses). (B) Increased endog-
enous RAG1 mRNA expression in immunized
mouse spleen. RAG1 mRNA levels were estimated
by RT-PCR. Sorted GFP2B2201 (GFP2),
GFP1B2201 (GFP1), and B2201 splenocytes from
mice immunized (1) 16 d earlier or unimmunized
(2) were analyzed. Serial fivefold dilutions of the
cDNA are shown. PCR for Igb is a cDNA loading
control. (C) RAG2-GFP and GL7 expression in
adoptively transferred RAG12/2 mice 16 d after
immunization with NP-CGG in alum. Histograms
show GFP and GL7 expression on B2201 spleen
cells. Percentage of cells found in each category is
indicated. R1, RAG1; RAG2-GFP, RAG2-GFP
mouse control; unimm., unimmunized control;
imm., immunized mice; TRSF imm., RAG12/2
mouse that received 3 3 107 RAG2-GFP spleen
cells 1 d before immunization.2116 Lymphopoiesis and Immune Responses
tinguishable from mice injected with NP-CGG in alum.
The number of GFP1 B cells in the spleen dropped to 36 6
12% of control on day 7 (n 5 5) and then increased to 189 6
26% of control on day 16 after alum injection (n 5 5).
These changes coincided with initial suppression of B lym-
phopoiesis followed by recovery at day 16. Furthermore,
CFA had similar effects on B lymphopoiesis (Table I).
Thus, altered lymphopoiesis in NP-CGG and alum–injected
mice is antigen independent and can be induced by either
alum or CFA.
In addition to suppressing B lymphopoiesis, adjuvant in-
jection also suppressed thymopoiesis. 4 d after administra-
tion of alum or CFA, the number of CD41CD81 thy-
mocytes decreased 7–50-fold (Fig. 4 B, and Table I). The
loss of CD41CD81 thymocytes was associated with an in-
crease in annexin V staining indicative of increased pro-
grammed cell death (Fig. 4 B). In contrast, the number of
myeloid cells in the bone marrow increased while the
number of erythroid cells was not significantly altered (Fig.
4 C). We conclude that administration of alum or CFA ini-
tially suppresses both T and B lymphopoiesis, that this ef-
fect is cell type and developmental stage specific, and that it
correlated with an increase in thymocyte apoptosis (21).
IFNs and TNF are known to suppress hematopoiesis
during certain viral infections (22, 23). For example, type I
IFNs are essential for suppression of hemato-lymphopoiesis
after lymphocytic choriomeningitis virus (LCMV) infec-
tion (22). To determine whether suppression of lym-
phopoiesis by adjuvants is mediated by IFNs or TNF, we
injected type I IFNR2/2, TNF2/2, and STAT12/2 mice
with alum and examined B and T cell development on day
4 (12–14) (Fig. 5). Although we found significant differ-
Figure 3. Cell cycle analysis of
spleen B cells from immunized
mice. RAG2-GFP mice were
immunized with NP-CGG in
alum and analyzed at day 16. (A)
Histograms show DNA content
of GFP2GL7high (G1), GFP1
GL7low  (G2), and GFP1GL72
(G3) B cells. The gates are
shown on the density plot. (B)
Expression of Fas in B2201GL71
GFP1 (G1 in A) and B2201
GL71GFP2 (G2 in A) spleen
cells at day 16 of NP-CGG/
alum immunization. Numbers
are percentages of cells within
the marked area.
Figure 4. Changes in hemato-lymphopoiesis af-
ter injection with NP-CGG in alum. (A) Bone
marrow pro-B, pre-B, and immature B cells. B6
mice were immunized with NP-CGG in alum, and
bone marrow cells obtained from a single femur
were analyzed. Cells with the B220lowCD431
HSAhighIgM2, B220lowCD432HSAhighIgM2, and
B220lowIgM1 phenotypes were counted as pro-,
pre-, and immature B cells, respectively. Mean 6
SE (n 5 4–5) is shown. (B) Thymocytes: increased
cell death in the thymus 4 d after alum injection.
Density plots show B6 thymocytes stained with
anti-CD4 and anti-CD8. Percentage of CD41
CD81 cells is indicated. Histograms show annexin
V staining on gated populations of CD41CD81
(DP) and CD41CD82 (SP) thymocytes. Control
mice were not injected with alum. (C) Myeloid
and erythroid cells obtained from single femurs.
Ly-6G1B2202DX52 and Ly-6G2B2202DX52
cells were counted as myeloid or erythroid/others
respectively. Mean 6 SE (n 5 3–4) is shown.
Altered B Lymphopoiesis Induced by Adjuvants or Infectious
Agents. As noted above, B lymphopoiesis is initially sup-
pressed by intraperitoneal injection with NP-CGG in
alum. To determine which stages of B cell development are
affected, we immunized B6 mice and counted B cell pro-
genitors in the bone marrow (Fig. 4 A). We found that
pro-B cell, pre-B cell, and immature B cell numbers are all
reduced by 5–20-fold by day 4 after immunization but all
of these precursors recover by day 16. In contrast, mature B
cell numbers in the spleen change little with immunization
(not shown). We conclude that immunization with NP-
CGG in alum initially suppresses B lymphopoiesis.
To determine whether the effect of NP-CGG plus alum
is antigen dependent, we injected RAG2-GFP indicator
mice and controls with alum alone. Such mice were indis-2117 Nagaoka et al.
ences in the magnitude of the adjuvant-induced suppres-
sion of lymphopoiesis in the different control mouse
strains, the absence of type I IFNR, STAT1, or TNF had
no effect on adjuvant-mediated suppression of B or T lym-
phopoiesis. We conclude that neither type I IFNR, nor
STAT1, nor TNF is essential for the suppression of lym-
phopoiesis by adjuvant.
Adjuvants are thought to impact the immune system by
some of the same mechanisms as natural infections. To de-
termine whether lymphopoiesis is also suppressed during
acute infection, we exposed mice to P. yoelii. At the peak of
parasitemia, day 14 after infection, the number of B220low
immature B lineage cells in the bone marrow was severely
reduced (Fig. 6), but the number of developing B cells re-
covered and even increased by day 28 when the malaria
parasites had been cleared (24). We conclude that the de-
velopment of immature B lineage cells is suppressed during
malaria infection, as it is after administration of adjuvants.
Discussion
RAG2-GFP indicator mouse strains produced by two
different technologies have been used to examine RAG ex-
pression in vivo (9–11). In one case, GFP was targeted into
RAG2 to produce a locus that directs the synthesis of a
RAG2-GFP fusion protein (9). The dynamic range of GFP
fluorescence in this strain is about one log over background
and to enhance detection analyses must be performed in
homozygous mutant mice (9). The second indicator strain
carries a 165-kb bacterial artificial chromosome transgene
in which GFP was inserted into the RAG2 gene (10). In
this transgenic indicator strain, GFP is not produced as a
fusion protein and fluorescence levels are much higher,
with a dynamic range of three to four logs. The half-life
and precise specific activity of the targeted RAG2-GFP fu-
sion protein are not known, but a clear disadvantage of the
transgenic system is that the half-life of the GFP indicator
in this strain is 2–3 d, probably much longer than that of
the endogenous RAG2 protein. However, despite the dif-
ferences between the two indicator strains, and the long
half-life of the transgenic GFP, the results reported for the
two indicator strains are very similar (9, 10). In both cases,
there were two peaks of RAG2-GFP indicator gene ex-
pression in developing B cells corresponding to two waves
of RAG transcription during heavy and light chain gene
recombination (4, 5, 9, 10). In addition, both indicator
strains showed GFP expression in immature B cells in the
bone marrow and spleen (9, 10). The amount of endoge-
nous RAG mRNA found in immature B cells was in-
versely correlated with the levels of surface IgM expression
and up to two orders of magnitude lower than that found
in pro- or pre-B cells (9, 10). Immature B cells with the
highest levels of surface IgM had exceedingly low levels of
Table I. Effect of Adjuvant Injection on T and B Lineage Cells
Number of cells (3105)
Cell PBS Alum CFA
Bone marrow*
Total 106.38 6 9.93 126.67 6 3.33 112.67 6 7.22
Pro-B 1.02 6 0.17 0.12 6 0.01‡ 0.12 6 0.03‡
Pre-B 5.52 6 0.69 0.62 6 0.11‡ 1.05 6 0.20‡
Immature B 2.31 6 0.41 0.45 6 0.07§ 0.36 6 0.10§
Recirculating B 7.67 6 1.48 0.35 6 0.12‡ 0.20 6 0.08‡
Myeloid 37.50 6 2.97 85.28 6 4.97‡ 65.92 6 3.16‡
Thymus
Total 772.50 6 52.82 64.67 6 21.36‡ 136.67 6 50.44‡
DP 440.87 6 41.69 9.06 6 4.08‡ 61.46 6 26.37‡
Spleen
B 26.01 6 1.78 26.37 6 0.34 28.56 6 3.02
T 13.37 6 1.37 10.06 6 0.55 10.14 6 0.68
Reagents were intraperitoneally injected 4 d before analysis. Numbers
are mean 6 SE (n 5 3 or 4). Pro-B, B220lowCD431HSAhighIgM2;
Pre-B, B220lowCD432HSAhighIgM2; Immature B, B220lowIgM1;
Recirculating B, B220high; Myeloid, Ly-6G1B2202DX52; DP,
CD41CD81; T, CD31.
*Number of cells/femur.
‡P , 0.01.
§P , 0.05.
Figure 5. STAT12/2, type I IFNR2/2, and TNF2/2 mice are suscep-
tible to alum-mediated suppression of lymphopoiesis. Mice with null mu-
tations of Stat1, Ifnar, or Tnf were injected with alum 4 d before analysis.
B220low cells from a single femur and CD41CD81 (DP) thymocytes were
counted and compared with background-matched controls. u, unin-
jected wild-type mouse; j, injected wild-type mouse; s, uninjected
knockout mouse; d, injected knockout mouse; W, wild-type; 2/2,
knockout.
Figure 6. B220/IgM staining of bone marrow cells from malaria-
infected mice. Date after infection is shown above the density plots and
parasitemia below. Percentages of B220low cells and absolute cell numbers
3106 (shown in parentheses) are indicated.2118 Lymphopoiesis and Immune Responses
RAG mRNA, below the dynamic range of detection in
the targeted indicator strain, and the significance of this low
level of RAG expression has yet to be determined.
Several groups have shown that immunization increases
RAG expression in B cells in peripheral lymphoid organs,
raising the possibility that RAG could be reinduced in ma-
ture B cells (6–9). In our initial experiments, we found that
RAG expression was not reinduced in mature B cells after
immunization and we were unable to induce RAG expres-
sion in vitro with LPS plus IL-4 (10). Nevertheless, there is
an increase in the number of RAG2-GFP–expressing B
cells in spleens of mice injected with alum. Most of these
cells are not of splenic origin, they are nondividing cells
that carry the cell surface markers of immature B cells.
Only a subset of the GFP1 B cells in the spleen is rapidly
proliferating, and a small subfraction of these rapidly divid-
ing cells expresses high levels of both GL7 and Fas, which
are markers of GC B cells (19, 20). Therefore, most GFP1
B cells found in the spleen on day 16 after injection with
alum are immature, and only a very small number of these
cells have the characteristics of GC cells. It has been pro-
posed that RAG expression in peripheral B cells might
contribute to further diversification of the antibody reper-
toire in GCs during immune reactions (6–8, 25, 26). Our
results suggest that antibody gene replacement in GCs is a
rare event. However, inflammatory or pathological pro-
cesses that lead to accumulation of immature B cells might
increase the frequency of such events (16, 27).
What is the origin of the RAG2-GFP–expressing cells
that accumulate in the spleen after immunization? Imma-
ture B cells are thought to be produced by the bone mar-
row at a steady rate of 1–2 3 107/d, and homeostasis main-
tained by selecting a variable fraction of these cells into the
long-lived B cell compartment (28–33). However, our ex-
periments suggest that the increase in RAG2-GFP–express-
ing B cells found in the spleen after immunization is due to
an increase in immature B cell production and export 12 d
after initial suppression of B lymphopoiesis by adjuvant.
This rebound effect resembles the increase in immature B
cell production and emigration from the bone marrow
found 12–14 d after sublethal irradiation (17) and differs
from the augmentation of pre-B cell production observed
4 d after injection with sheep RBCs (34). We conclude that,
like irradiation, adjuvants and infection affect lymphopoie-
sis and alter the rates of immature B cell production and
export from the bone marrow.
Transient suppression of B and T lymphopoiesis has
been reported during infection with LCMV and after IFN
injection, but these agents produced a more general sup-
pression of hematopoiesis not found with adjuvant injec-
tion (22, 35). In LMCV infection, bone marrow suppres-
sion is mediated by type I IFNs (22), but neither type I
IFNs, nor STAT1, nor TNF were essential for the effect
produced by alum injection.
What is the significance of altering lymphopoiesis after
administration of adjuvant or during infection? Alterations
in lymphopoiesis could be limited to malaria and LCMV,
and to administration of CFA or alum, and therefore have
little physiological significance. However, the documented
suppressive effects of inflammatory cytokines, IFNs, and
TNF on lymphopoiesis (36–39) suggest that any infectious
or inflammatory agent that significantly increases the pro-
duction of these cytokines and possibly other such effectors
may alter lymphopoiesis. Therefore, subsets of T and B
cells recently exported from the bone marrow or thymus
may resemble myeloid cells, which display well-character-
ized shifts during infection and inflammation. Such shifts in
the composition of the lymphocyte populations might
change the outcome of immune responses. In particular,
immature B cells recently emigrating from the bone mar-
row are highly susceptible to tolerance and less likely to en-
ter the memory pool (40–45). Thus, decreasing the num-
ber of such cells exported in acute infection may protect
against tolerance and indirectly enhance B cell memory.
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